3MCDONALD M G, RIEDER M J, NAKANO M, et al. CYP4F2 is a vitamin K1 oxidase:an explanation for ahered warfarin dose in carriers of the V433M variant [J]. Mol Pharmaco1,2009,75 ( 6 ) : 1337-1346.
4D' ANDREA G, D'AMBROSIO R L, PEMA P D, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-antociagulant effect of warfarin [ J ]. Blood, 2005,105 ( 2 ): 645-649.
5STUBBINS M J, HARRIES L W, SMITH G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus [ J ]. Pharm acogenetics, 1996,6 ( 5 ) : 429-439.
6TAUBE J, HALSALL D, BAQLIN T. Influence of cytoc- hrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over anticoagulation in patients on long-term treatment [ J]. Blood ,2000,96( 5 ) : 1816-1819.
7HIGASHI M K, VEENSTRA D L, KONDO L M, et al. Association between CYP2C9 genetic variants and an ticoagulation-related outcomes during warfarin therapy [ J ]. JAMA,2002,287 ( 13 ): 1690-1698.
9TOPIC E, STEFANOVIC M, SAMARDZIJA M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype [ J ]. Clin Chem Lab Med,2004,42 ( 1 ) :72-78.
9WANN L S, CURTIS A B, JANUARY C T, et al. 2011 ACCF/AHA,/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline) :a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[ J ]. Heart Rhythm, 2011,8 ( 1 ) : 157 -176.
10WALDO A L, BECKER R C, TAPSON V F, et al. Hos- pitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate antieoagulation [J]. J Am Coll Cardiol,2005,46(9):1729-1736.
